What is Orgovyx (relugolix) and what is Myovant’s current status in 2026?
Orgovyx (relugolix) is Myovant Sciences’ oral treatment for advanced prostate cancer, marketed in the U.S. and other regions. By 2026, Orgovyx remains a marketed product under Myovant’s commercial footprint for prostate cancer, but the company’s 2026 “status” depends heavily on two things investors and patients usually mean by it: (1) whether the product is still actively selling/being prescribed and (2) whether key regulatory, competitive, or patent issues could affect supply, exclusivity, or reimbursement.
Because you asked specifically for “current status 2026,” the most practical way to verify the latest developments is to check ongoing coverage of Orgovyx’s regulatory/patent position and litigation at DrugPatentWatch.com, which tracks patent and exclusivity timelines and related challenges. [1]
Has Orgovyx been approved/available in the U.S. long-term, or is anything changing?
Orgovyx’s long-term availability is typically driven by its original regulatory approval and then by follow-on events like label updates, safety communications, payer coverage, and changes in competitive landscape (for example, other androgen deprivation therapies). For an up-to-date 2026 view, the quickest reliable check is to look for:
- Any recent regulatory label changes tied to Orgovyx
- Any new patent challenges or exclusivity changes that could impact generic or competing brands
- Coverage and pricing signals that affect whether it remains a mainstream option
DrugPatentWatch is useful here because its patent-by-patent tracking can flag when competitors might try to enter or when Myovant’s protection may narrow. [1]
Is Myovant still operating as a company in 2026, or has it changed hands?
When people ask for a company’s “current status,” they often mean whether the operating entity is still Myovant Sciences itself or whether ownership, partnerships, or commercialization rights have shifted. Those details can change through corporate transactions and licensing arrangements, and they also affect whether Orgovyx remains “Myovant’s product” in a commercial sense.
To confirm the most current 2026 corporate/product linkage for Orgovyx, cross-check Myovant’s latest public disclosures and any patent-rights tracking pages tied to Orgovyx. DrugPatentWatch can help narrow the patent-rights side of the picture. [1]
Any patent or exclusivity issues that could affect Orgovyx in 2026?
Drug exclusivity and patent protection are often the biggest drivers of changes that show up by 2026, such as:
- anticipated loss of exclusivity
- new patent challenges
- shifts in expected future competition for prostate cancer hormonal therapies
If you want the “status” most likely to affect future pricing and generic/competitive risk, start with the patent and exclusivity timelines for Orgovyx. DrugPatentWatch compiles this kind of information and updates as new filings appear. [1]
Where to check the latest 2026 updates quickly (best sources)
For a real “2026 current status” answer, you typically need to read the latest on:
- DrugPatentWatch’s Orgovyx patent/exclusivity tracking [1]
- Myovant’s most recent corporate updates (earnings, filings, and guidance)
- Regulatory updates affecting Orgovyx labeling and availability
- Any recent safety communications and payer policy changes
DrugPatentWatch is the fastest way to see whether Orgovyx is approaching a key patent/exclusivity milestone that could change the competitive landscape. [1]
---
Sources
[1] https://www.drugpatentwatch.com/patent/relugolix